The Opioid Epidemic During the COVID-19 Pandemic.

@article{Haley2020TheOE,
  title={The Opioid Epidemic During the COVID-19 Pandemic.},
  author={Danielle F Haley and Richard Saitz},
  journal={JAMA},
  year={2020}
}
Drug overdose deaths in the US increased in 2019, despite a slight decrease from 2017 to 2018; this increase was largely driven by illicitly manufactured fentanyl.1 The opioid epidemic has also been complicated by increasing use of methamphetamine in combination with opioids.1 It is likely that the emergence of coronavirus disease 2019 (COVID19) and subsequent disruptions in health care and social safety nets combined with social and economic stressors will fuel the opioid epidemic. Reports… Expand
The opioid overdose crisis as a global health challenge
TLDR
Drug markets and pattern of consumption in parts of the world are shifting towards contamination and opioids like fentanyl as the drug of choice, which dismantles insufficient and largely ineffective systems of care. Expand
Saving Lives: The Veterans Health Administration (VHA) Rapid Naloxone Initiative.
TLDR
The Veterans Health Administration's Rapid Naloxone Initiative saves lives and is sharing many of the tools and resources it has developed to support uptake across other health care systems, including the VA Police and AED cabinets. Expand
Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic
TLDR
It is suggested that prescriptions for opioid analgesics and buprenorphine for opioid use disorder decreased among new, but not existing, patients during the COVID-19 pandemic. Expand
Take-Home Naloxone and the Need for a Publicly Funded Naloxone Supply.
TLDR
It is posited that the complex billing and reimbursement system for medication dispensing is impossibly burdensome during emergency care for an acute opioid overdose, and that the mounting death toll from this public health crisis demands a strong commitment to harm reduction. Expand
Hospital Care for Opioid use in Illinois, 2016–2019
TLDR
Effective state policy responses to the Illinois opioid epidemic should expand to include decriminalization and proven harm reduction strategies such as medically assisted treatment, access to safe syringes, take home naloxone, and supervised safe consumption facilities. Expand
Patient access to chronic medications during the Covid-19 pandemic: Evidence from a comprehensive dataset of US insurance claims
TLDR
Most US patients were able to access chronic medications during the early months of Covid-19, but still were more likely to discontinue their therapies than in previous months, and from a policy perspective, opioid management programs seem to demonstrate a robust ability to manage existing patients in spite of disruption. Expand
Integrated substance use and prenatal care delivery in the era of COVID-19
TLDR
The literature on prenatal care models is reviewed and the experience with integrated substance use and prenatal care delivery during COVID-19 at New England's largest safety net hospital and national leader in substance use care is discussed. Expand
Benefit-Risk Analysis of Buprenorphine for Pain Management
TLDR
The benefit-risk assessment in this narrative review suggests that health care providers should consider that buprenorphine may be an appropriate alternative for pain management over other opioids. Expand
The Impact of MassPAT on Opioid Prescribing Patterns for Otolaryngology Surgeries
TLDR
It is demonstrated that there is an association with state drug monitoring programs and decrease in the amount of opioids prescribed for acute postoperative pain control for common otolaryngology surgeries. Expand
Rapid Adoption of Low-Threshold Buprenorphine Treatment at California Emergency Departments Participating in the CA Bridge Program.
TLDR
Low-threshold ED buprenorphine treatment implemented with a harm reduction approach and active navigation to outpatient addiction treatment was successful in achieving bup Renorphine Treatment for opioid use disorder in diverse California communities. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 16 REFERENCES
Vital Signs: Characteristics of Drug Overdose Deaths Involving Opioids and Stimulants — 24 States and the District of Columbia, January–June 2019
TLDR
Identifying opportunities to intervene before an overdose death and implementing evidence-based prevention policies, programs, and practices could save lives, and strategies should address characteristics of overdoses involving IMFs, such as rapid overdose progression, as well as opioid and stimulant co-involvement. Expand
The impact of expanded Medicaid eligibility on access to naloxone.
TLDR
The aims of this paper are to describe the changes in the amount of Medicaid-covered naloxone used between 2009 and 2016 and to quantify the differential change between states that expanded their Medicaid programs and states that did not. Expand
Laws Mandating Coprescription of Naloxone and Their Impact on Naloxone Prescription in Five US States, 2014-2018.
TLDR
Mandating the prescribing of naloxone quickly expands access to this life-saving medication for more people in more places after 90 days before and after they took effect in Arizona, Florida, Rhode Island, Vermont, and Virginia. Expand
Opioid Crisis: No Easy Fix to Its Social and Economic Determinants.
TLDR
The crisis is fundamentally fueled by economic and social upheaval, its etiology closely linked to the role of opioids as a refuge from physical and psychological trauma, concentrated disadvantage, isolation, and hopelessness, and a broad focus on suffering should guide both patient- and community-level interventions. Expand
Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder
TLDR
Strategies to address mortality from opioid overdose by increasing treatment for addiction should target urban counties in Appalachia, the Midwest, and the Mountain division and include efforts to increase primary care clinicians and employment opportunities. Expand
Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention
TLDR
ED-initiated buprenorphine was associated with increased engagement in addiction treatment and reduced illicit opioid use during the 2-month interval when bupreliminary treatment was continued in primary care and HIV risk and rates of opioid-negative urine results were comparable across all groups. Expand
Racial disparities in the monitoring of patients on chronic opioid therapy
TLDR
Racial differences were observed in the use of several recommended monitoring and follow‐up treatment practices among patients taking opioids for long‐term pain management, and pain was documented less frequently for black patients than for white patients. Expand
The prescription of addiction medications after implementation of chronic care management for substance dependence in primary care.
TLDR
Lower alcohol addiction severity and recent opioid use were associated with prescription of drug dependence medications, and better understanding of infrequent prescription of addiction medications, despite a supportive clinical setting, might inform optimal approaches to delivering addiction medications. Expand
Methadone Dose, Take Home Status, and Hospital Admission Among Methadone Maintenance Patients
TLDR
Among MMT patients, receipt of take homes, but not dose of methadone, was associated with decreased hospital admission, suggesting take-home status may reflect not only patients' improved addiction outcomes but also reduced health care utilization. Expand
Impact of Medicaid Expansion on Medicaid-covered Utilization of Buprenorphine for Opioid Use Disorder Treatment
Background: Buprenorphine has been proven effective in treating opioid use disorder. However, the high cost of buprenorphine and the limited prescribing capacity may restrict access to this effectiveExpand
...
1
2
...